Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yonsei Univ. College of Medicine JAK1 compound 46
- Development stage
- Unknown
- Lead developer
- Yonsei University College of Medicine
01
Overview
Yonsei Univ. College of Medicine JAK1 compound 46: sourced facts only. name: "It is of note that 46 has 4-fold higher enzymatic activity against JAK1 (IC50 = 0.022 μM) relative to 9." [PMID:39892337]; target: "It is of note that 46 has 4-fold higher enzymatic activity against JAK1 (IC50 = 0.022 μM) relative to 9." [PMID:39892337]; developer: "KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea; Department of Biomedical Sciences, Graduate School of Medical Science, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea." [PMID:39892337]
02
Targets
Beyond the preview
Go deeper on Yonsei Univ. College of Medicine JAK1 compound 46.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yonsei Univ. College of Medicine JAK1 compound 46.